Stem cells are used to treat Parkinson’s disease by replacing the dopamine-producing brain cells that the disease destroys. In Parkinson’s, a specific population of neurons in the brain gradually dies off, leaving patients with progressively worsening tremors, stiffness, and difficulty moving. The core idea behind stem cell therapy is straightforward: grow new dopamine-producing neurons in a lab, then surgically transplant them into the brain region where they’re needed. Several clinical trials are now testing this approach in humans, with early results showing meaningful improvements in motor function.
Why Dopamine Replacement Matters
Parkinson’s disease kills neurons that produce dopamine, a chemical messenger essential for smooth, coordinated movement. Standard medications work by boosting dopamine levels artificially, but they become less effective over time and can cause side effects like involuntary movements. Stem cell therapy aims to solve the problem at its root by introducing new cells that can produce dopamine on their own, potentially restoring a more natural supply directly inside the brain.
How the Cells Are Made
Researchers start with either embryonic stem cells or induced pluripotent stem cells (iPSCs), which are adult cells reprogrammed back into a flexible, stem-like state. Both types can be coaxed in the lab to become dopamine neuron precursors. The process typically takes about two weeks of guided development in specialized growth solutions. At a key stage, cells are sorted using a surface marker called CORIN, which identifies cells destined to become dopamine neurons while filtering out unwanted cell types. The final product in one major trial contained roughly 60% dopamine precursors and 40% mature dopamine neurons.
Quality control at this stage is critical. Sorting for the right markers helps eliminate undifferentiated stem cells that could, in theory, form tumors after transplantation. Researchers also screen to confirm that no serotonin-producing neurons have developed in the batch, since those cells have been linked to involuntary movements in earlier transplant experiments.
Embryonic vs. Reprogrammed Cells
Embryonic stem cells currently have a more established track record in generating dopamine neurons. Single-cell analysis has shown that embryonic cells produce a broader diversity of mature cell types, including dopamine neurons and supportive brain cells called astrocytes, while iPSC-derived cultures tend to contain more immune cells and fewer neurons. However, iPSCs carry a major practical advantage: they can be made from a patient’s own skin or blood cells, which could reduce or eliminate the need for immune-suppressing drugs after transplantation. Both approaches are being tested in active clinical trials.
The Surgical Procedure
The cells are delivered through stereotactic neurosurgery, a precise technique that uses brain imaging to guide a thin needle to an exact location. The target is the putamen, the part of the brain where dopamine is normally released to coordinate movement. The procedure is performed under general anesthesia. Surgeons deposit the cells as a suspension through a small opening in the skull, placing them directly where dopamine signaling has been lost.
The surgery itself is relatively brief compared to other brain procedures, but the real timeline extends months and years afterward. Transplanted precursor cells need time to mature into fully functioning dopamine neurons, form connections with surrounding brain tissue, and begin producing dopamine at meaningful levels.
What Early Trials Have Found
Two landmark Phase 1 trials published in Nature in 2025 have provided the strongest evidence yet that this approach works in humans.
A trial using embryonic stem cell-derived neurons (a therapy called bemdaneprocel, developed by BlueRock Therapeutics) found that patients receiving the higher dose showed an average 23-point improvement on a standard motor function scale at 18 months after transplantation. That scale, the MDS-UPDRS Part III, measures tremor, rigidity, walking ability, and other movement symptoms. A 23-point change is clinically significant. The lower-dose group improved by about 9 points on average. No patients in either group developed graft-induced dyskinesias, the involuntary movements that plagued some earlier fetal tissue transplant experiments.
A separate Japanese trial using iPSC-derived dopamine cells confirmed that the transplanted cells survived in the brain, actively produced dopamine, and did not form tumors. This was the first trial to demonstrate the safety of iPSC-derived neurons in Parkinson’s patients.
Based on these results, the FDA granted bemdaneprocel a Regenerative Medicine Advanced Therapy (RMAT) designation, which makes it eligible for expedited review and a potential path to accelerated approval.
Immune Suppression After Transplant
When transplanted cells come from a donor rather than the patient’s own body, the immune system will treat them as foreign and try to destroy them. This means patients receiving donor-derived cells need long-term immunosuppressive medication, similar to what organ transplant recipients take.
Experience from earlier fetal tissue transplants showed this is not optional. Patients who stayed on continuous immunosuppression for years had the best outcomes and remained resistant to graft-induced dyskinesias. Those who stopped their immune-suppressing drugs often saw their improvements fade, and some developed involuntary movements afterward. The best results came from patients who received long-term, uninterrupted treatment.
This is one reason autologous iPSC therapies, which use a patient’s own reprogrammed cells, are so appealing. One such trial (ANPD001, run by Aspen Neuroscience) is currently enrolling patients and following them for five years post-transplant, with safety monitoring extending to 15 years total. If cells derived from the patient’s own body can survive without immunosuppression, it would remove one of the biggest burdens of this therapy.
Who Qualifies for Treatment
Current clinical trials are generally looking for patients in the moderate stages of Parkinson’s, not those with very early or very advanced disease. Typical eligibility criteria include an age range of 18 to 75, a confirmed Parkinson’s diagnosis for at least five years, and a disease severity rating between stages 2 and 4 on the Hoehn and Yahr scale (a five-point scale where 1 is mild, one-sided symptoms and 5 is wheelchair-bound or bedridden). Patients also need to have been on stable medication, including levodopa, for at least a year.
Earlier transplant research found that patients with a more intact dopamine system at the time of surgery tended to do better. This makes sense: the transplanted cells need a reasonably healthy surrounding environment to integrate and function. Patients whose disease has already caused extensive brain-wide damage may not benefit as much, which is why trials generally exclude the most advanced cases.
How Long Recovery Takes
Stem cell therapy for Parkinson’s is not an instant fix. The transplanted precursor cells need months to mature, extend their connections, and begin releasing dopamine in a functionally useful way. In the BlueRock trial, motor improvements were measured at 18 months post-surgery, suggesting the cells were actively integrating over that period. Some patients may notice gradual changes earlier, but the full effect takes time to develop.
This is fundamentally different from taking a pill that works within hours. The transplanted cells are essentially rebuilding a piece of the brain’s dopamine circuitry from scratch, and biological growth happens on its own schedule. Trial participants typically continue their regular Parkinson’s medications during this period, with the expectation that doses could potentially be reduced as the graft matures.
Where Things Stand Now
Stem cell therapy for Parkinson’s is in late-stage clinical testing but not yet commercially available. The bemdaneprocel program is the furthest along, with its RMAT designation clearing a path toward a Phase 2 trial and potential accelerated approval. The Aspen Neuroscience autologous iPSC trial is estimated to run through 2030. Several other trials are active in Japan, China, and Europe.
The results so far represent a genuine shift from decades of incremental progress. Earlier attempts using fetal brain tissue showed that the concept worked but faced problems with inconsistent cell quality, ethical concerns about tissue sourcing, and immune rejection. Today’s stem cell-derived neurons are manufactured under controlled conditions, sorted for purity, and screened for safety in ways that fetal tissue never could be. The 23-point motor improvement seen in the high-dose bemdaneprocel group, with no graft-induced dyskinesias, is the clearest signal yet that lab-grown dopamine neurons can meaningfully help people with Parkinson’s disease.